Clinical Trial Detail

NCT ID NCT00801489
Title Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin

Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin

Age Groups: adult senior

No variant requirements are available.